Novo Nordisk has announced the launch of a discounted subscription offer for its obesity drug Wegovy, specifically targeting US patients without insurance coverage. Monthly prices will be reduced to $329 for a 3-month commitment, $299 for six months, and $249 for one year, down from the standard $349. These offers will be available through telehealth platforms such as Ro, WeightWatchers and LifeMD, representing discounts of up to nearly 30%.

This move comes amid intensifying competition with Eli Lilly, whose drug Zepbound continues to win market share. Both companies are adopting similar strategies, combining direct sales with digital health partnerships to capture and retain new patients. However, these pricing policies are weighing on margins, with some analysts suggesting that Novo Nordisk could face greater exposure due to more aggressive discounting.

Beyond pricing, this shift reflects a broader market transformation where patients are becoming consumers who are increasingly sensitive to transparency and ease of access. Pharmaceutical companies are gradually moving away from traditional insurance-dominated channels towards consumer-centric models that are based on pricing flexibility and direct-to-patient access.